TABLE 3.

Mixed model analysis: the estimates, SE, and P values for changes in outcome measures from baseline for each treatment at each time point.

	4 wk	12 wk	24 wk	36 wk	48 wk	Treatment comparisona
B&B
Levlen/NS
n	23	19	14	15	14
Coefficient	–1.22	–1.48	–1.80	–0.97	–1.40
SE	0.45	0.47	0.50	0.50	0.50
P value	0.0112	0.0035	0.0009	0.0578	0.0082	.95, SE = ±0.57 (P= .10)
Leuprolide/norethindrone
N	14	15	12	13	10
Coefficient	–1.88	–2.18	–2.77	–2.36	–2.71
SE	0.50	0.50	0.52	0.51	0.55
P value	.0006	.0001	< .0001	< .0001	< .0001
ISS
Levlen/NS
n	16	12	11	11	9
Coefficient	1.42	–1.15	–1.34	–0.51	–2.41
SE	1.63	1.72	1.76	1.79	1.82
P value	.3934	.513	.4523	.7775	.1959	4.69, SE = ±2.72, (P= .10)
Leuprolide/norethindrone
n	10	10	8	10	10
Coefficient	0.20	–3.58	–9.32	–8.91	–12.18
SE	3.27	3.28	3.85	3.45	3.45
P value	.9515	.2846	.0208	.0148	.0013
BDI
Levlen/NS
n	20	20	16	15	14
Coefficient	–2.41	–3.92	–5.22	–4.70	–6.53
SE	1.20	1.20	1.26	1.28	1.30
P value	.0536	.0029	.0002	.0008	< .0001	–0.84, SE = ±1.59, (P=.60)
Leuprolide/norethindrone
n	15	15	13	13	11
Coefficient	–0.75	–3.94	–6.26	–4.18	–3.72
SE	1.55	1.55	1.64	1.64	1.73
P value	.6325	.0158	.0005	.0145	.0369
NRS
Levlen/NS
n	23	20	16	15	14
Coefficient	–2.25	–2.43	–2.82	–2.55	–2.53
SE	0.51	0.54	0.57	0.58	0.59
P value	.0001	< .0001	< .0001	< .0001	< .0001	–0.11, SE = ±0.61, (P=.85)
Leuprolide/norethindrone
n	16	15	13	13	10
Coefficient	–1.04	–2.08	–3.59	–3.21	–3.56
SE	0.44	0.46	0.49	0.49	0.54
P value	.0236	< .0001	< .0001	< .0001	< .0001

^aComparison of treatments by mixed models effect. Listed are the estimated coefficient ±SE and P value.